

## Bioventus to Release Fourth Quarter and Fiscal Year 2020 Financial Results on March 25, 2021

March 1, 2021

DURHAM, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdag: BVS) ("Bioventus" or the "Company"). a global leader in innovations for active healing, today announced that fourth quarter and fiscal year 2020 financial results will be released after the market closes on Thursday, March 25, 2021.

Management will host a conference call to discuss its financial results and provide a business update, with a question and answer session, at 5:00 p.m. Eastern Time on March 25, 2021. Those who would like to participate may dial 844-945-2085 (442-268-1266 for international callers) and provide access code 2158468. A live webcast of the call and any accompanying materials will also be provided on the investor relations section of the Company's website at <a href="https://ir.bioventus.com/">https://ir.bioventus.com/</a>.

The webcast will be archived on the Company's website at <a href="https://ir.bioventus.com/">https://ir.bioventus.com/</a> and available for replay until March 25, 2022.

## **About Bioventus**

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit <a href="https://www.bioventus.com">www.bioventus.com</a> and follow the company on <a href="https://www.bioventus.com">LinkedIn</a> and <a href="https://www.bioventus.com">Twitter</a>. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Media Contact: Thomas Hill 919-474-6715 thomas.hill@bioventusglobal.com Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke/ICR Investor.relations@bioventus.com